Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 198

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 198
---
, other outbreaks of illness or public health events, fires or natural or man-made disaster or act of God, including any worsening of such conditions 
 existing as of the date of the Merger Agreement; or                                                                                                                                                                                                                                                                                                                                                                           |

| (H) | any failure by Clearwater to meet, or changes to, internal or analysts’ estimates, projections,                                                                                                                                                      
 expectations, budgets or forecasts of operating statistics, revenue, earnings, cash flow or any other financial or performance measures (whether made by Clearwater or any third parties), any change in Clearwater’s credit ratings, or any change  
 in the price or trading volume of shares of Clearwater Common Stock (the underlying causes of such failures or changes in this clause (J) may be taken into account in determining whether a Clearwater Material Adverse Effect has occurred, unless 
 such underlying cause would otherwise be excepted by this definition);                                                                                                                                                                               |

providedthat in the case of clauses (B), (D), (E) and (G), any Effect may be taken into account in determining whether or not there has been a Clearwater Material Adverse Effect, but only to the extent such Effect has had or would reasonably be expected to have, individually or in the aggregate, a disproportionate adverse effect on Enfusion and its subsidiaries, taken as a whole, as compared to other similarly situated participants in the industry in which Enfusion and its subsidiaries operate, in which case only the incremental disproportionate impact or impacts may be taken into account in determining whether or not there has been a Clearwater Material Adverse Effect. Conduct of Business of Enfusion Prior to Completion of the Transactions For purposes of this Proxy Statement/Prospectus and the Merger Agreement: “ Enfusion Employee Plan” means (i) each “employee benefit plan,” within the meaning of Section 3(3) of ERISA, whether or not subject to ERISA, (ii) each employment, severance or similar contract, plan, arrangement, or policy and (iii) each other plan or arrangement providing for compensation or benefits (including variable cash compensation and sales commissions), incentive, bonuses, profit-sharing, stock, stock option or other equity-related rights (including restricted stock units and stock purchase rights) or other forms of incentive or deferred compensation, health or medical care and benefits, employee assistance program, education or tuition assistance programs, disability, hospitalization, death or sick leave benefits, supplemental unemployment benefits, severance benefits, post-employment or retirement benefits, termination, change in control, retention, pension, savings, vacation